Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
Dominik DeniffelNathan PerlisSangeet GhaiStephanie GirgisGerard M HealyNeil FleshnerRobert HamiltonGirish KulkarniAnts ToiTheodorus van der KwastAlexandre ZlottaAntonio FinelliMasoom A HaiderPublished in: European radiology (2022)
• In men undergoing MRI-targeted biopsy, the risk of detecting clinically significant prostate cancer (csPCa) only on additional systematic biopsy (SBx) decreased in men with PI-RADS 5, previous negative biopsy, and younger age. • Using these variables may help select men who could avoid the risk of excess SBx. • If missing csPCa in 5% was acceptable, forgoing SBx in men with PI-RADS 5 and/or previous negative biopsy enabled the highest net reduction in SBx.